Literature DB >> 24750987

Participation of hypertension patients in early-phase clinical trials.

Paul Borron1, Oren Cohen, Theo J Hoofwijk, J Rick Turner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24750987      PMCID： PMC8032192          DOI： 10.1111/jch.12296

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  11 in total

1.  The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.

Authors:  Thomas Hünig
Journal:  Nat Rev Immunol       Date:  2012-04-10       Impact factor: 53.106

2.  Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.

Authors:  Robert B Parker; Judith E Soberman
Journal:  Pharmacotherapy       Date:  2011-07       Impact factor: 4.705

3.  Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients.

Authors:  Maria Czarina Acelajado; Roberto Pisoni; Tanja Dudenbostel; Suzanne Oparil; David A Calhoun; Stephen P Glasser
Journal:  J Am Soc Hypertens       Date:  2011-10-22

Review 4.  Rational use of antihypertensive medications in children.

Authors:  Michael A Ferguson; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2013-05-29       Impact factor: 3.714

5.  Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial.

Authors:  Carol P Wilson; Helene McNulty; Mary Ward; J J Strain; Tom G Trouton; Birgit A Hoeft; Peter Weber; Franz F Roos; Geraldine Horigan; Liadhan McAnena; John M Scott
Journal:  Hypertension       Date:  2013-04-22       Impact factor: 10.190

Review 6.  First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials.

Authors:  Adel Nada; John Somberg
Journal:  Am J Ther       Date:  2007 Nov-Dec       Impact factor: 2.688

7.  Hypertension is associated with serologically active disease in patients with systemic lupus erythematosus: role of increased Th1/Th2 ratio and oxidative stress.

Authors:  M A B Lozovoy; A N C Simão; H K Morimoto; T M V Iryioda; C Panis; E M V Reiche; S D Borelli; S R Oliveira; R Cecchini; I Dichi
Journal:  Scand J Rheumatol       Date:  2013-10-18       Impact factor: 3.641

Review 8.  Clinical trials in new drug development.

Authors:  J Rick Turner; Theo J Hoofwijk
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-03-13       Impact factor: 3.738

9.  Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels.

Authors:  Dimitris P Papadopoulos; Iordanis Mourouzis; Charles Faselis; Despina Perrea; Thomas Makris; Costas Tsioufis; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-02-12       Impact factor: 3.738

10.  Common ALDH2 genetic variants predict development of hypertension in the SAPPHIRe prospective cohort: gene-environmental interaction with alcohol consumption.

Authors:  Yi-Cheng Chang; Yen-Feng Chiu; I-Te Lee; Low-Tone Ho; Yi-Jen Hung; Chao A Hsiung; Thomas Quertermous; Timothy Donlon; Wei-Jei Lee; Po-Chu Lee; Che-Hong Chen; Daria Mochly-Rosen; Lee-Ming Chuang
Journal:  BMC Cardiovasc Disord       Date:  2012-07-29       Impact factor: 2.298
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.